



PRESS RELEASE

Synthego and Biomay Collaborate to Accelerate Access to mRNA manufacturing and CRISPR Solutions

Redwood City, CA, and Vienna, Austria – October 1st, 2026. Biomay, a contract development and manufacturing organization (CDMO) specializing in mRNA manufacturing, lipid nanoparticle (LNP) formulation, aseptic fill-finish, plasmid DNA, and recombinant proteins, and Synthego, a leading provider of CRISPR solutions, today announced a non-exclusive collaboration to market, promote, and resell Biomay products and services to Synthego customers and end users in North America.

The collaboration is designed to help customers accelerate their CRISPR programs by providing streamlined access to gRNA manufacturing, mRNA manufacturing, LNP formulation, aseptic fill-finish, critical gene-editing components and cGMP manufacturing capabilities. It brings together Biomay's expertise in the development and manufacturing of Cas9 nuclease, mRNA, and related products with Synthego's expertise in CRISPR gene-editing solutions, including the design and manufacturing of single-guide RNA (sgRNA).

Key elements of the collaboration include:

- **Distribution of Biomay off-the-shelf products**, including Cas9 recombinant nuclease and Cas9-encoding mRNA (available for research-use-only / RUO and cGMP applications)
- **Integrated cGMP offerings for CRISPR workflows**, combining Biomay's mRNA manufacturing, LNP formulation, aseptic fill-finish and Cas9 manufacturing capabilities with Synthego's sgRNA expertise
- **Custom cGMP mRNA manufacturing services, including** LNP formulation and aseptic fill-finish, supporting gene-editing and other advanced therapeutic applications

More information on key offerings mentioned here can be found on www.synthego.com and biomay.com.

"We are pleased to enter into this collaboration with a pioneering CRISPR solutions provider like Synthego," said **May Guo, VP Business Development** of Biomay. "Synthego's expertise in CRISPR solutions and the design and manufacturing of single-guide RNA is highly complementary to Biomay's manufacturing capabilities for Cas9 and mRNA. By combining our complementary capabilities, we can make it easier for customers to access the critical components and cGMP manufacturing services they need, helping them accelerate their gene-editing programs from early development toward the clinic."

Hana Kim, PhD, Director of Clinical Product Management of Synthego added: "Biomay brings extensive experience in cGMP mRNA manufacturing, LNP formulation, and aseptic fill-finish, as well as the manufacture of critical gene-editing components, including Cas9 nuclease. Biomay is the manufacturer of the Cas9 nuclease used in CASGEVY®, the first approved CRISPR/Cas9-based therapy. Together, Biomay's capabilities and Synthego's CRISPR and guide RNA expertise provide customers with a more streamlined path to high-quality materials and services for gene-editing programs."

About Synthego

Synthego empowers agility across life science research and therapeutic development by providing unparalleled access to best-in-class CRISPR solutions and scalable molecular biology reagents. From



flexible licensing to end-to-end technical, regulatory, and diagnostic support, Synthego de-risks critical workflows to accelerate the discovery and delivery of next-generation therapeutics and patient diagnostics. As a pioneering leader advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise, Synthego enables improved outcomes in the design of patient therapeutics and human health.

About Biomay

Biomay is a fully integrated CDMO based in Vienna, Austria. Biomay offers cGMP services for the manufacturing of mRNA, circular plasmid DNA, linear IVT-template DNA, and therapeutic recombinant proteins (clinical and commercial). The company's services include process and analytical development, cell banking, R&D material supply, cGMP manufacturing, LNP formulation, and aseptic fill-finish. Biomay's manufacturing facilities are multiple times inspected by the U.S. FDA.

Contact:

Synthego Holdings LLC

Synthego Media Relations

press@synthego.com

www.synthego.com

Biomay AG

May Guo

Vice President Business Development

request@biomay.com

www.biomay.com